Navigation Links
Statins stop hepatitis C virus from replicating

A new study shows that statins, which are typically used as anti-cholesterol medications, can inhibit the replication of the hepatitis C virus (HCV). They could replace ribavirin in combination therapy with interferon. These findings are published in the July 2006 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). Published by John Wiley & Sons, Inc., Hepatology is available online via Wiley InterScience at

Currently, 170 million people worldwide are infected with HCV. The standard treatment is a combination therapy of interferon and ribavirin, which is only effective in about 55 percent of patients. The remaining 45 percent face a threat of the disease progressing to cirrhosis and liver cancer. Based on recent reports that one statin, lovastatin, inhibits HCV replication, researchers led by Masanori Ikeda of Okayama University in Japan, tested other statins in search of a more effective anti-HCV therapy.

Using the OR6 cell culture assay system, they evaluated the anti-HCV activities of five statins: atorvastatin, fluvastatin, lovastatin, pravastatin and simvastatin. When the statins were tested alone, all except pravastatin inhibited HCV replication. Fluvastatin had the strongest effect. Atorvastatin and simvastatin had moderate effects while lovastatin had a weak effect. While pravastatin exhibited no anti-HCV activity, it did work as an inhibitor for HMG-CoA reductase, suggesting that the anti-HCV activities of the other stains are not due to the direct inhibition of HMG-CoA.

The researchers determined that the anti-HCV activities of statins were not related to cytotoxicity, meaning they did not kill the host cell. Additional experiments also suggested that, "the statins possess the ability to inhibit the replication of HCV RNA via a specific antiviral mechan ism," the authors report.

The researchers tested the theory that certain proteins are required for HCV RNA replication and that statins block the replication by inhibiting those proteins. In support of this theory, they found that the addition of both mevalonate and geranylgeraniol restored HCV RNA replication in the statin-treated cells.

To evaluate statins as potential replacements for ribavirin in combination therapy, the researchers tested the anti-HCV activities of each one when combined with interferon. Each combination, except the one including pravastatin, had even stronger inhibitory effects on HCV RNA replication than when the statin was used alone. Again, fluvastatin plus interferon exhibited the strongest effect. "We clearly demonstrated that co-treatment of interferon and fluvastatin was an overwhelmingly effective treatment," the authors report. This combined therapy was more effective against HCV RNA replication than interferon alone and more effective than the standard combination therapy of interferon and ribavirin.

"Statins are good reagents for combination therapy with interferon in patients with chronic hepatitis C," the authors conclude. "Furthermore, our developed OR6 assay system will be useful for the time-saving screening of new anti-HCV reagents."


Source:John Wiley & Sons, Inc.

Related biology news :

1. Statins have neutral effect on risk of cancer
2. Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis
3. Scalpel-free surgery could reduce risk of HIV and hepatitis exposure for health care workers
4. Researchers create infectious hepatitis C virus in a test tube
5. New tools used to control foodborne hepatitis A outbreaks related to green onions
6. Studies clarify risk factors for mother-to-child transmission of hepatitis C virus
7. Past illegal blood donation in China linked to hepatitis C virus infection
8. Texas scientists discover how a hepatitis C protein promotes liver cancer
9. U of S researchers develop new vaccine candidate against hepatitis C
10. Cyclosporine inhibits hepatitis C virus in vitro
11. Novel therapy combinations gain ground in treating hepatitis
Post Your Comments:

(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced that Lenovo has selected Synaptics , ... FS4202, for its latest smartphone, the Vibe P1. The ... to unlock the device and provide swift access to ... The feature-rich Natural ID FS4202 sensor solution utilizes AES256-bit ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... Mass. , Oct. 13, 2015 Applied ... methodologies at critical decision points throughout the drug invention ... QSP Congress Boston 2015 on October 20-22, 2015 in ... Burke , PhD, Co-Founder, President, and CEO of Applied ... discovery from early research to clinical trials" on Wednesday ...
(Date:10/13/2015)... PARK, N.J. and SAN DIEGO ... (BASF) and Mast Therapeutics, Inc. have agreed to collaborate ...  Currently, excipient-grade poloxamer 188 NF, marketed by BASF under ... used in a variety of pharmaceutical and biological applications, ... Poloxamer 188 is the starting material for Mast,s lead ...
(Date:10/13/2015)... and TORONTO , Oct. 13, 2015 /PRNewswire/ ... that it has entered into a non-binding Letter of Intent ... Israeli company that has developed a proprietary cooling technology designed ... varicoceles. the United States and ... the ages of 25 and 44 diagnosed as infertile.  For ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... is excited to announce their partnership with the Keck Medicine of the ... chronic pain. , The T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical Objectives Linking ...
Breaking Biology Technology: